Initially exploiting the proprietary DCOne® platform, DCprime is developing cell based vaccines against different types of cancer. These vaccines have as a primary goal to provide safe and active protection against reoccurrence of disease (so-called relapse). By boosting the immune system’s ability to recognize specific tumour antigens, cancer vaccines are expected to improve immune surveillance against tumour cells carrying these antigens, thereby preventing or delaying their manifestation as a new tumour. Cell based cancer vaccines also combine well with other immuno-oncology approaches, to make possible the development of disruptive new combination therapies against hard-to-treat tumour types.